ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Establishment Labs to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 3, 2022 GMT

SANTA BARBARA, Calif.--(BUSINESS WIRE)--Jan 3, 2022--

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 1:30pm Eastern Time.

A live webcast of the presentation will be available on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. An archived version of the webcast will be available on the same website following the completion of the event.

ADVERTISEMENT

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness. The company’s initial focus is breast health, principally breast aesthetics and reconstruction. Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva Implants ® that include a number of innovative and patented features designed to deliver improved aesthetic and clinical outcomes. Since commercial launch in 2010, more than 1.8 million Motiva Implants ® have been delivered to plastic surgeons in over 80 countries. The company also offers or has under development a number of related products and technologies, including the Motiva Flora ® tissue expander and Motiva MIA ®, the company’s minimally invasive breast enhancement procedure. In 2018, Establishment Labs received an investigational device exemption (IDE) from the FDA for the Motiva Implant ® and began a clinical trial to support regulatory approval in the United States. Motiva Implants ® are manufactured at the company’s two facilities in Costa Rica, which are compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. Please visit our website for additional information at www.establishmentlabs.com.

ADVERTISEMENT

View source version on businesswire.com:https://www.businesswire.com/news/home/20220103005102/en/

CONTACT: Investor/Media Contact:

Raj Denhoy

415-828-1044

rdenhoy@establishmentlabs.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA

INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES CONSUMER WOMEN SURGERY OTHER HEALTH GENERAL HEALTH

SOURCE: Establishment Labs Holdings Inc.

Copyright Business Wire 2022.

PUB: 01/03/2022 08:00 AM/DISC: 01/03/2022 08:02 AM

http://www.businesswire.com/news/home/20220103005102/en